Biogened S.A. (WSE: BGD)
Health Care · Pharmaceuticals · PL
zł19.90
+0.51% today · -16.8% 1Y
Biogened S.A. (WSE: BGD) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $12.41M.
Over the last twelve months the share price has lost 16.8%, trading between 17.30 and 25.60.
Tweenvest scores Biogened S.A. across four factors: quality 77/100, value 68/100, growth 78/100, dividend 59/100. Its strongest factor is growth.
BGD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $12.41M
- Revenue (TTM)
- $29.26M
- P/E
- 9.49
- EPS
- 2.09
- Dividend yield
- 2.53%
- Beta (5Y)
- -0.01
- 52-week high
- zł25.60
- 52-week low
- zł17.30
- Avg volume (3M)
- —
- Shares outstanding
- 2.46M
- Employees
- —
- Next earnings
- —
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Silco Pharmaceuticals LimitedDSE: SILCOPHL | $12.90M | Tk15.30 | -8.38% |
| Anebulo Pharmaceuticals, Inc.OTCPK: ANEB | $12.85M | $0.32 | -1.56% |
| Intravenous Infusions PlcGHSE: IIL | $12.84M | GH₵0.55 | +12.24% |
| FLUENT Corp.CNSX: FNT.U | $12.76M | $0.02 | -20.00% |
| Krebs Biochemicals & Industries LimitedBSE: 524518 | $12.41M | Rs55.72 | -19.71% |
| Liven Pharma LimitedKASE: LIVEN | $12.40M | PKRs30.37 | -2.47% |
| Alpa Laboratories LimitedNSEI: ALPA | $12.39M | Rs56.99 | -3.83% |
| Rize Oncology Inc.OTCPK: RZON.F | $12.12M | $— | — |
Figures last refreshed Oct 11, 2026.